2,350,010 Shares in OptiNose, Inc. (NASDAQ:OPTN) Purchased by Stonepine Capital Management LLC

Stonepine Capital Management LLC bought a new stake in OptiNose, Inc. (NASDAQ:OPTN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,350,010 shares of the company’s stock, valued at approximately $2,444,000. OptiNose makes up about 2.2% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 10th largest position. Stonepine Capital Management LLC owned about 2.08% of OptiNose at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. HighMark Wealth Management LLC acquired a new position in shares of OptiNose in the first quarter valued at approximately $36,000. XTX Topco Ltd purchased a new position in shares of OptiNose during the 2nd quarter worth $88,000. Squarepoint Ops LLC lifted its stake in shares of OptiNose by 173.7% during the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares during the period. Oracle Investment Management Inc. acquired a new stake in shares of OptiNose during the first quarter worth $474,000. Finally, Easterly Investment Partners LLC grew its position in shares of OptiNose by 10.2% in the second quarter. Easterly Investment Partners LLC now owns 2,246,224 shares of the company’s stock valued at $2,336,000 after purchasing an additional 208,185 shares during the period. 85.60% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Ramy A. Mahmoud sold 111,426 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the completion of the sale, the chief executive officer now directly owns 1,206,978 shares in the company, valued at approximately $1,375,954.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Ramy A. Mahmoud sold 111,426 shares of OptiNose stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total value of $127,025.64. Following the transaction, the chief executive officer now directly owns 1,206,978 shares of the company’s stock, valued at approximately $1,375,954.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael F. Marino III sold 49,408 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total value of $56,325.12. Following the sale, the insider now owns 550,464 shares of the company’s stock, valued at approximately $627,528.96. The disclosure for this sale can be found here. Insiders have sold a total of 167,679 shares of company stock valued at $191,154 over the last quarter. Company insiders own 2.70% of the company’s stock.

OptiNose Trading Down 4.1 %

OptiNose stock opened at $0.67 on Tuesday. The stock has a fifty day moving average price of $0.94 and a 200 day moving average price of $1.10. OptiNose, Inc. has a 52 week low of $0.67 and a 52 week high of $2.10. The firm has a market capitalization of $75.74 million, a P/E ratio of -2.48 and a beta of -0.04.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $20.49 million for the quarter, compared to analyst estimates of $20.81 million. As a group, equities analysts predict that OptiNose, Inc. will post -0.22 EPS for the current year.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.